DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
CC-122 is an investigational drug.
There have been 13 clinical trials for CC-122. The most recent clinical trial was a Phase 1 trial, which was initiated on May 1st 2019.
The most common disease conditions in clinical trials are Lymphoma, Lymphoma, Large B-Cell, Diffuse, and Lymphoma, Non-Hodgkin. The leading clinical trial sponsors are Celgene Corporation, Celgene, and Bristol-Myers Squibb.
There are thirty-nine US patents protecting this investigational drug and four hundred and twenty-seven international patents.
Recent Clinical Trials for CC-122
|Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma||Bristol-Myers Squibb||Phase 2|
|Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma||Celgene Corporation||Phase 2|
|Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma||H. Lee Moffitt Cancer Center and Research Institute||Phase 2|
Top disease conditions for CC-122
Top clinical trial sponsors for CC-122
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|CC-122||Start Trial||Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers||Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)||Start Trial|
|CC-122||Start Trial||Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies||Celgene Corporation (Summit, NJ)||Start Trial|
|CC-122||Start Trial||Formulations of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione||Celgene Corporation (Summit, NJ)||Start Trial|
|CC-122||Start Trial||Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast||Celgene Corporation (Summit, NJ)||Start Trial|
|CC-122||Start Trial||Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases||CELGENE CORPORATION (Summit, NJ)||Start Trial|
|CC-122||Start Trial||Methods to induce targeted protein degradation through bifunctional molecules||Dana-Farber Cancer Institute, Inc. (Boston, MA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|CC-122||European Patent Office||EP3313818||2035-06-26||Start Trial|
|CC-122||World Intellectual Property Organization (WIPO)||WO2016210262||2035-06-26||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|